A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis

ConclusionComparable efficacy and safety outcomes were observed between male and female patients with active AS treated with secukinumab over 52  weeks. Further, sex was not an independent predictor of treatment response to secukinumab as assessed by ASAS40 responder rates and BASDAI change from baseline; association of ASDAS-CRP ID responder rates with sex warrants further exploration.Trial registrationClinicalTrials.gov; NCT01358175, NCT01649375, NCT02008916, NCT02159053, and NCT02896127.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research